PUH-71 is under clinical development by Samus Therapeutics and currently in Phase I for Myeloproliferative Disorders. According to GlobalData, Phase I drugs for Myeloproliferative Disorders have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PUH-71’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PUH-71 overview
PUH-71 is under development for the treatment of myeloproliferative neoplasms, metastatic breast cancer, primary myelofibrosis, post-polycythemia vera MF, acute myelocytic leukemia and post-essential thrombocytopenia. The therapeutic candidate is administered through intravenous and oral routes. The drug candidate acts by targeting a purine scaffold, heat shock protein 90 (HSP90). The drug candidate was also under development for the treatment of T cell acute lymphocytic leukemia, Non-Hodgkin's lymphoma, and advanced solid tumors.
For a complete picture of PUH-71’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
